Clinical trials: Percutaneous Coronary Intervention Patients
No Reflow Phenomenon, Reperfusion Injuries, Myocardial
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
Study Background \& Purpose: The no-reflow phenomenon is a significant complication occurring in patients with acute myocardial infarction who undergo percutaneous coronary intervention (PCI).
- Conditions
- No Reflow Phenomenon, Reperfusion Injuries, Myocardial, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT07898709
- Testing
- Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment
- Where
- 4 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Al-Azhar University
Coronary Artery Disease (CAD)
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
To determine the efficacy of prasugrel versus clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting…
- Trial name
- TRIGGER-PCI (NCT00910299)
- Testing
- Prasugrel, Clopidogrel
- Where
- 27 sites in United States, Germany
- Volunteers
- 423 people
- Sponsor
- Eli Lilly and Company
Insulin Resistance and PCI
Impact of Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
Full myocardial reperfusion with restoration of coronary microcirculatory function (CMF) is a therapeutic goal in ST-segment elevation myocardial infarction (STEMI).1 Despite the success of primary percutaneous coronary…
- Trial name
- NCT04651842
- Testing
- PCI
- Where
- Egypt
- Volunteers
- 240 people
- Sponsor
- Assiut University
Coronary Disease
Effects of Atorvastatin on Myonecrosis
This study is designed as a prospective, randomized, placebo-controlled, double-blind analysis of atorvastatin 80 mg versus placebo administered on average 4 hours prior to percutaneous coronary intervention [PCI] (at least 2…
- Trial name
- NCT00344019
- Testing
- Atorvastatin 80mg, Screening
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Beth Israel Deaconess Medical Center
Renal Insufficiency, Chronic, Cardiac Catheterization
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as…
- Conditions
- Renal Insufficiency, Chronic, Cardiac Catheterization, Percutaneous Coronary Intervention
- Trial name
- NCT05225077
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Dong-A University
Heart Failure With Reduced Ejection Fraction, Ischemic Cardiomyopathy
Revascularization Versus Medical Treatment in Patients With Ischemic Left Ventricular Dysfunction
Randomized trial to compare clinical outcomes between revascularization versus medical treatment alone in patients with ischemic cardiomyopathy and left ventricular dysfunction.
- Trial name
- RESTORE-PCI (NCT05828719)
- Testing
- Percutaneous coronary intervention
- Where
- South Korea
- Volunteers
- 900 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease
Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Early stent thrombosis has been noted with increased frequency in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) who are treated with bivalirudin and clopidogrel.
- Trial name
- NCT01789814
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Tufts Medical Center
Primary PCI for STEMI
Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention (PCI)
200 consecutive patients presenting with STEMI within 12 hours from the onset of symptoms and having a high thrombotic burden at coronary angiography, defined as the presence of a thrombus size ≥ 2 times the diameter of the…
- Trial name
- NCT01472718
- Testing
- coronary thrombectomy, standard primary PCI (with stenting, as required)
- Volunteers
- 208 people
- Sponsor
- University of Pisa
Acute Myocardial Infarction, Phase I Cardiac Rehabilitation
The Impact of Phase I Cardiac Rehabilitation on the Prognosis of AMI Patients After PCI
Previous research has confirmed that patients undergoing percutaneous coronary intervention (PCI) can benefit from cardiac rehabilitation programs.
- Trial name
- AID (NCT06406218)
- Testing
- Phase I Cardiac Rehabilitation Exercise Training
- Where
- China
- Volunteers
- 1,100 people
- Sponsor
- Han Yaling, MD
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
No-Reflow Phenomenon
Intracoronary Tirofiban on No-Reflow Phenomena
The goal of this study was to evaluate the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with STEMI and occurrence of no-reflow phenomenon undergoing primary percutaneous coronary…
- Trial name
- NCT02054000
- Testing
- Tirofiban
- Where
- Turkey (Türkiye)
- Volunteers
- 162 people
- Sponsor
- TC Erciyes University
Patients Who Are Scheduled to Undergo a PCI (Percutaneous Coronary Intervention) for CTO (Chronic Total Occlusion)
TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization
The study is a single-centre, randomized, active controlled, open label clinical trial. The primary hypothesis is that ticagrelor will show superiority over clopidogrel immediately after CTO-PCI (chronic total occlusion …
- Trial name
- TIGER-BVS (NCT02211066)
- Testing
- Clopidogrel, Ticagrelor
- Where
- 2 sites in Spain
- Volunteers
- 59 people
- Sponsor
- Hospital Clinic of Barcelona
Right Coronary Artery Occlusion
Right Ventricular Function Change After PCI to Right Coronary Artery
Proximal RCA occlusions were very often found among men with fatal pre-hospital MI; whereas left-sided coronary occlusions were significantly more frequent in hospital-admitted survivors of MI.
- Trial name
- NCT03543345
- Testing
- echocardiography study
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Chronic Renal Failure
Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure
This study is to evaluate the efficacy of sodium bicarbonate plus N-acetylcysteine for the prevention of contrast-induced nephropathy.
- Trial name
- NCT00716001
- Testing
- N-acetylcysteine
- Sponsor
- Osaka General Medical Center
Congenital Heart Disease
Safety and Effectiveness of the Device "Nit-Occlud® PDA-R"
The purpose of this study is to evaluate the safety and the effectiveness of the device "Nit-Occlud® PDA-R" in the percutaneous closure of patent ductus.
- Trial name
- NCT01063712
- Testing
- Nit-Occlud® PDA-R
- Where
- Bolivia
- Volunteers
- 29 people
- Sponsor
- pfm S.R.L.
Coronary Arterial Disease (CAD), Coronary Microvascular Dysfunction (CMD)
Prognostic Values of Coronary Microvascular Dysfunction Patients Treated with Rotational Atherectomy During Percutaneous Coronary Intervention
The goal of this observational study is to learn about the long-term prognostic of coronary microvascular dysfuction in Patients Treated with Rotational Atherectomy During Percutaneous Coronary Intervention.
- Trial name
- NCT06702748
- Where
- China
- Volunteers
- 452 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Myocardial Infarction
Effects of Early Statin Treatment After Acute Myocardial Infarction (AMI) in Japanese Patients
Statins have been shown to prevent coronary artery disease and to preserve left ventricular function in dilated cardiomyopathy. The investigators hypothesized that the early use of statins would reduce cardiovascular events…
- Trial name
- NCT00128024
- Testing
- lipid-lowering treatment
- Where
- Japan
- Volunteers
- 460 people
- Sponsor
- Kumamoto University
ST-segment Elevation Myocardial Infarction (STEMI)
Efficacy of Thrombus Aspiration in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Prospective, Multicenter, Randomized, Controlled, Single-Blind Clinical Trial
The goal of this clinical trial is to learn if adding standardized manual thrombus aspiration to primary percutaneous coronary intervention (PPCI) works better to improve heart health outcomes and protect long-term heart function…
- Trial name
- TRAP-MI (NCT07551700)
- Testing
- Manual Thrombus Aspiration, Primary Percutaneous Coronary Intervention (PPCI)
- Volunteers
- 6,760 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Acute Coronary Syndrome, Atrial Fibrillation
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
The selection of the optimal antithrombotic therapy in patients with nonvalvular atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is challenging.
- Trial name
- EPIDAURUS (NCT04981041)
- Testing
- Prasugrel or Ticagrelor, Clopidogrel
- Where
- 37 sites in Austria, Germany
- Volunteers
- 602 people
- Sponsor
- Ludwig-Maximilians - University of Munich